- $1.68bn
- $1.43bn
- $655.35m
Novocure Ltd reports results for the quarter ended June 30 - Earnings Summary
Novocure Q2 revenue beats, lifts 2026 outlook
Brief: Novocure Q2 Revenue USD 183.584 Million Vs. IBES Estimate USD 172.4 Million
U.S. STOCKS ON THE MOVE-Kardigan, Energy companies, Take-Two, Accenture
U.S. STOCKS ON THE MOVE-Kardigan, Energy companies
U.S. STOCKS ON THE MOVE-Pfizer, Accenture, Kroger
Novocure tanks after cancer treatment fails to meet late-stage trial goal
Early use of Novocure's brain cancer therapy shows no significant survival benefit in late-stage trial (updated)
Novocure's cancer treatment fails to meet late-stage trial goal
Novocure Q1 revenue rises 12%, beats analyst estimates; raises outlook
Brief: Novocure Q1 Revenue USD 174.055 Million Vs. IBES Estimate USD 167.9 Million
Novocure Q4 revenue slightly beats expectations, margins drop
Brief: Novocure Ltd Says CMS Reinstates Medicare Billing Privileges Retroactively - SEC Filing
Brief: FDA Approves First-Of-Its-Kind Device To Treat Pancreatic Cancer
Press Digest: Wall Street Journal - February 12
Brief: Novocure Appoints Company President Frank Leonard As Chief Executive Officer
Novocure Q3 revenue beats estimates
Brief: Novocure Q3 Revenue USD 167.204 Million Vs. IBES Estimate USD 158.6 Million
Brief: Novocure To Report Third Quarter 2025 Financial Results